onyx liquid embolic system

The Onyx Liquid Embolic System is a liquid embolic agent composed of ethylene vinyl alcohol copolymer dissolved in dimethyl sulfoxide (DMSO). It is used in endovascular embolization procedures to occlude blood vessels in the treatment of arteriovenous malformations and other vascular lesions.

Common clinical scenarios for the Onyx Liquid Embolic System include the embolization of arteriovenous malformations, dural arteriovenous fistulas, and other vascular abnormalities. It is often used when traditional surgical approaches are not feasible.

The available literature includes 15 studies, with a mix of randomized controlled trials, case series, and retrospective analyses. The studies span from 2017 to 2026, providing a comprehensive overview of the device's clinical applications.

Published studies report that the Onyx Liquid Embolic System is effective in achieving vascular occlusion in various clinical settings, including the embolization of the middle meningeal artery for chronic subdural hematoma. The device has demonstrated good radiopacity and handling characteristics in clinical use.

Reported complications include inflammatory changes and potential adverse reactions related to the embolic material. However, the studies did not provide detailed safety outcomes, indicating a need for further research into long-term safety profiles.

The evidence base is limited by the lack of large-scale randomized controlled trials and detailed safety data. Further research is needed to establish long-term outcomes and to better understand the potential complications associated with the device.